Bedrijfsoverzicht
Lucyd, Inc. is a specialized manufacturer focused on the development and commercialization of smart eyeglasses and sunglasses within the North American market. The company's flagship offering, the Lucyd Lyte, is engineered to facilitate hands-free functionality, allowing users to listen to music, execute voice calls, and utilize voice assistants and ChatGPT for smartphone tasks without physical interaction. This business operates within the Healthcare sector, specifically categorized under the Medical Instruments & Supplies industry, which typically implies a focus on innovative tools that enhance patient care or diagnostic capabilities, although the specific product line here targets consumer utility. The company currently maintains a market capitalization of $6.80M, reports annual revenue of $2.66M, and employs a workforce of 13 individuals. These financial figures indicate that Lucyd, Inc. operates as a small-cap entity with limited operational scale relative to established industry peers. The low employee count combined with the modest revenue base suggests the company is in an early stage of market penetration or is heavily reliant on capital-intensive R&D rather than mass production scaling at this time. The valuation metrics further contextualize this scale, as the market capitalization is derived from a stock trading range between $0.95 and $4.97, reflecting significant price volatility common in emerging technology firms.
Financiële gezondheid
The financial statements for Lucyd, Inc. show a trailing twelve-month revenue of $2.66M, while the net income for the same period stands at -$7,591,189, and the EBITDA is reported at -$8,359,622. The substantial negative gap between the positive revenue of $2.66M and the large negative net income reveals a cost structure where expenses, including likely significant R&D and operating costs, vastly exceed the gross profits generated by sales. The company reports a free cash flow of -$5,588,018, which indicates that the business is burning cash to fund its operations and product development, thereby limiting its immediate financial flexibility to pay down debt or return capital to shareholders. Profitability is analyzed through three distinct margins: a gross margin of 21.3%, an operating margin of -260.4%, and a profit margin of -285.2%. The negative operating and profit margins indicate that operating expenses are more than double the revenue, while the positive gross margin suggests that the cost of goods sold is managed reasonably well despite the overall losses. On the balance sheet, the company holds $6.51M in cash and maintains $0 in debt, creating a situation where liquid assets significantly outweigh liabilities. The debt-to-equity ratio is listed as N/A due to the absence of debt, which implies a conservative balance sheet structure free from leverage obligations. Liquidity is further supported by a current ratio of 9.03, indicating that the company possesses more than nine times the current assets necessary to cover its short-term liabilities. Return metrics show a Return on Equity of -83.6% and a Return on Assets of -53.2%, revealing that management has not yet generated positive returns on the capital invested in the business.
Waarderingsbeoordeling
Valuation multiples for Lucyd, Inc. present a complex picture due to the company's unprofitable status, with a trailing P/E ratio of N/A and a forward P/E of -2.40. The forward P/E of -2.40, calculated on negative earnings, implies that the market is pricing the stock based on future turnaround expectations rather than current profitability, though it does not suggest a specific earnings trajectory since the company is currently loss-making. The price-to-book ratio stands at 0.65, indicating that the market values the company at 65% of its book value, which typically suggests the stock is trading at a discount relative to its net asset value. Alternative valuation metrics include a price-to-sales ratio of 2.56 and an EV/EBITDA of -0.04, which provide context for investors looking beyond traditional earnings-based multiples. The 52-week high for the stock is $4.97 and the 52-week low is $0.95, meaning the current price sits at a level that reflects high volatility within this specific trading range. The beta value is 3.06, which signifies that the stock price is expected to be 3.06 times more volatile than the broader market, exposing investors to substantial price swings. These valuation metrics collectively suggest that the stock is priced with high risk premiums associated with small-cap biotech or medical device companies that are still in the development or early commercialization phase.
Growth & Income
Lucyd, Inc. demonstrates a revenue growth rate of 39.0% year-over-year, while the earnings growth rate is listed as N/A due to the company's lack of profitability. The absence of positive earnings growth relative to revenue growth implies that while top-line sales are expanding rapidly, the company has not yet achieved the operational efficiencies required to convert that revenue into net income. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning no dividends are distributed to shareholders. This zero payout ratio confirms that the company reinvests all available cash flow, however negative, into research and development to fuel future growth rather than providing income to investors. The overall growth and income profile is characterized by rapid revenue expansion coupled with significant losses and zero dividend income, highlighting a strategy focused on long-term market capture rather than immediate financial returns.